CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.
Researchers observed greater OS improvement among women without primary platinum-refractory disease, results presented at ASCO Annual Meeting showed.
“There remains a large unmet need for effective and well-tolerated treatments for women with platinum-resistant ovarian cancer,” Nicoletta Colombo, MD, PhD, associate professor of obstetrics and gynecology at University of Milan-Bicocca in